- Tuesday, December 21, 2010
- Published at:Int J Clin Pharmacol Ther. 2010 Dec;48(12):854-9
Appropriate use of oral drops: perception of health professionals and assessment of package insert information.
Zaid AN, Al-Ramahi R, Abu Ghoush A.
1Department of Pharmaceutics and Pharmacokinetics, and 2Department of Pharmacology and Toxicology, School of Pharmacy, An-Najah National University, Nablus, Palestine.
Objectives: To evaluate the perception of health professionals and industry personnel towards the appropriate use of oral drops and to assess their package inserts with regard to presence of proper instructions for use and storage. Methods: The first part was a cross-sectional self-administered questionnaire. The questionnaires were distributed randomly to physicians, pharmacists and decision makers in local pharmaceutical companies. In the second part, the package inserts of medications with oral drops were reviewed to check for presence of proper instructions for storage and proper use. Results: The majority of physicians and pharmacists (73.3% and 71.2%) t
- Sunday, October 3, 2010
- Published at:International Journal of Clinical Pharmacology and Therapeutics, Vol. 48 &amp;ndash; No. 9/2010 (571-576)
- Y. Hassan1, R.J. Al-Ramahi2, N.A. Aziz1 and R. Ghazali3
1School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia, 2School of Pharmacy, An-Najah National University, Nablus, Palestine, and 3Department of Medicine, Penang Hospital, Penang, Malaysia
Background and objective: Adverse drug events (ADEs) are a common cause of hospitalization and in-hospital complications. The aim of this study was to determine the rates, types, severity and preventability of pre-admission and in-hospital ADEs in patients with chronic kidney disease (CKD). Methods: This study was conducted at the nephrology unit at Penang General Hospital. A random sample of 300 adult patients with CKD was included. Medical records and charts were reviewed by a clinical pharmacist every work day to find any evidence of errors or complications related to drug use. If a suspected ADE was found, further investigations were carried out to assess the causality, severity and preventability of the event. Results: A total of 1
- Wednesday, December 30, 2009
- Published at:Ann Acad Med Singapore 2009;38:1095-103
Yahaya Hassan, Rowa’J Al-Ramahi, Noorizan Abd Aziz, Rozina Ghazali
One of the most important drug-related problems in patients with chronic kidney disease (CKD) is medication dosing errors. Many medications and their metabolites are eliminated through the kidney. Thus, adequate renal function is important to avoid toxicity. Patients with renal impairment often have alterations in their pharmacokinetic and pharmacodynamic parameters. The clearance of drugs eliminated primarily by renal fi ltration is decreased by renal disease. Therefore, special consideration should be taken when these drugs are prescribed to patients with impaired renal function. Despite the importance of dosage adjustment in patients with CKD, such adjustments are sometimes ignored. Physicians and pharmacists can work together to accomplish safe drug prescribing. This task can be complex and require a stepwise approach to ensure effectiveness, minimise further damage and prevent drug nephrotoxicity.
- Wednesday, September 23, 2009
- Published at:Annals of Pharmacotherapy 2009;43:1598-1605. DOI 10.1345/aph.1M187
- Yahaya Hassan, Rowa' J Al-Ramahi, Noorizan Abd Aziz, and Rozina Ghazali
BACKGROUND: Appropriate drug selection and dosing for patients with chronic kidney disease (CKD) is important to avoid unwanted drug effects and ensure optimal patient outcomes. OBJECTIVE: To assess the rate of inappropriate dosing in patients with CKD in a nephrology unit and to evaluate the impact on dose adjustment, adverse drug events (ADEs), and drug cost of having a pharmacist accompany a team of physicians on their rounds. METHODS: This was a comparative study with a preintervention and post-intervention design. The preintervention phase served as the control; it was prospective and observational only and was conducted from the beginning of February to the end of May 2007. The second phase (intervention phase) was conducted from the beginning of March to the end of June 2008. Two random samples of 300 patients with an estimated creatinine clearance less than or equal to 50 mL/min were included. During the intervention phase,